Artivion (AORT) Q4 2022: Stent Graft Growth Hits 20% as Supply Chain Stabilizes

February 16, 2023 | By EarningsIQ Research

Artivion’s Q4 revealed accelerating demand for stent grafts and On-X valves, with operational bottlenecks in Germany now easing as hiring surges. Margin pressure from inflation remains, but management signals confidence in sustaining double-digit growth and EBITDA expansion into 2024. Watch for execution on new product launches and regulatory catalysts to determine if Artivion can unlock its expanded addressable market.

Summary

• Stent Graft Momentum: High demand and staffing improvements in Germany are set to drive further growth.
• Margin Stabilization: Inflation-driven cost headwinds are now largely incorporated, with flat gross margins expected near term.
• Pipeline Catalysts: Upcoming regulatory decisions and clinical trial milestones could expand Artivion’s addressable market by $700M.

Business Overview

Artivion develops and commercializes medical devices and biologics for cardiac and vascular surgery, focusing on aortic repair and heart valve replacement. The company generates revenue through four main segments: stent grafts (endovascular aortic repair devices), On-X mechanical heart valves, tissue processing (preserved cardiac and vascular tissues), and BioGlue surgical sealant. Key growth regions include North America, Europe, Asia Pacific, and Latin America, with a growing presence in emerging markets supported by regulatory approvals and channel expansion.

Performance Analysis

Stent grafts led growth in Q4, up 16% constant currency, and closed the year at 20% growth—demonstrating robust demand and the payoff from recent manufacturing investments in Germany. On-X valves delivered double-digit gains (11% in Q4, 13% for the year), underpinned by their unique INR (International Normalized Ratio) profile, which allows for lower anticoagulation levels than competitors. Meanwhile, Asia Pacific and Latin America posted standout constant currency growth of 21% and 12% in Q4, and 30% and 38% for the full year, respectively, as investments in commercial infrastructure and regulatory wins took hold.

Gross margins compressed by about 150 basis points year-over-year to 64.5%, attributed to persistent inflation in labor and materials as well as product mix shifts. Management expects gross margins to stabilize at these levels in 2023, with improvement anticipated beyond that as supply chain and staffing issues resolve. Notably, TMR handpiece revenues will drop to near zero for at least two years following a supplier exit, but this is not seen as material to long-term growth. Adjusted EBITDA grew sequentially, and Artivion remains on track for its 2024 profitability targets.

• Regional Outperformance: Asia Pacific and Latin America outpaced other geographies, validating the channel expansion strategy.
• Product Mix Drag: BioGlue underperformed due to regulatory delays, but normalization is expected with the new CE mark secured.
• Expense Discipline: R&D and G&A spending remained controlled, with non-recurring costs isolated from core profitability metrics.

Artivion’s ability to translate top-line growth into EBITDA will hinge on operational execution as new hires in Germany ramp and regulatory catalysts materialize.

Executive Commentary

Strategic Positioning

1. Stent Graft Supply Chain Reset

Artivion’s largest growth driver, the stent graft portfolio, faced repeated supply constraints due to labor shortages in Germany. Management responded by increasing wages to attract talent, achieving near-full staffing by Q4. The company is now executing a logistics and consignment optimization project, with outside expertise brought in to ensure future scalability and prevent recurrence of bottlenecks. This operational reset is expected to unlock further growth as new hires complete training and production normalizes.

2. Diversified Global Growth Engines

Asia Pacific and Latin America have emerged as critical growth engines, with investments in sales infrastructure and regulatory clearances translating to outsized revenue gains. This geographic diversification reduces reliance on legacy European and North American markets, and positions Artivion to capture a larger share of the global aortic repair opportunity as emerging markets mature.

3. Pipeline and Regulatory Catalysts

Artivion is on the cusp of several major regulatory events: PerClot (surgical hemostat) is expected to receive FDA approval imminently, unlocking a $15M net milestone and initial shipments to Baxter. Proact Mitral (mitral valve) faces a more complex FDA path, with management openly hedging on timing and label scope due to trial design nuances. Two major clinical trials—AMDS Persevere and Endospan Nexus Triumph—are progressing, with potential approvals in 2025 that could expand the addressable market by $700M if endpoints are met and options exercised.

4. Margin Management in Inflationary Environment

Gross margin erosion from inflation in labor and materials is now largely “baked in,” with management planning for flat margins in 2023 and improvement thereafter. The company is shifting focus to higher-growth, higher-margin product lines, and deprioritizing low-contribution businesses such as TMR, which is being discontinued following supplier exit.

5. Financial Discipline and Capital Structure

Artivion maintains ample liquidity, with $39.4M in cash, $306M in debt, and a fully available $30M credit facility. Management does not anticipate needing to raise additional capital, even if interest rates rise. Debt covenants are not restrictive, and the company is targeting net leverage below 3x as EBITDA expands.

Key Considerations

Artivion’s Q4 performance highlights a business at an inflection point, with operational improvements and pipeline catalysts poised to drive the next leg of growth. However, execution risks remain as the company scales manufacturing and navigates regulatory complexity.

Key Considerations:

• Supply Chain Rebuild: New hiring and logistics projects must deliver sustained manufacturing reliability to meet high demand for stent grafts.
• Regulatory Approvals: Timely FDA decisions for PerClot and Proact Mitral are critical for near-term upside and long-term growth narrative.
• Margin Recovery: Success in stabilizing and improving gross margins will determine Artivion’s ability to convert sales growth into EBITDA leverage.
• Geographic Expansion: Continued outperformance in Asia Pacific and Latin America will be a key differentiator if momentum is maintained.
• Pipeline Execution: Clinical trial outcomes and subsequent product launches in 2025 could reshape Artivion’s market opportunity and competitive positioning.

Risks

Execution risk remains elevated as Artivion transitions its German manufacturing to higher output and integrates new staff. Regulatory uncertainty for Proact Mitral could delay or limit market access, while inflation and FX volatility may continue to pressure margins and top-line growth. The abrupt loss of TMR handpiece supply, although not material, underscores vulnerability in non-core product lines. Investors should monitor for any further supply chain disruptions or delays in key product approvals.

Forward Outlook

For Q1 2023, Artivion expects:

• Approximately $2M revenue headwind from currency versus Q1 2022
• First-half revenue growth at the lower end of the 8-12% full-year range, accelerating in the second half as new Germany hires ramp

For full-year 2023, management guided:

• Constant currency revenue growth of 8-12%, or $331M to $343M in sales
• Adjusted EBITDA of at least $50M, with a target to exceed this as operational leverage improves

Management highlighted that regulatory timing for PerClot and manufacturing ramp in Germany are pivotal swing factors for achieving the higher end of the range. Proact Mitral approval is not included in guidance and would represent upside if secured.

• Second-half FX could be a tailwind if Euro/USD rates move favorably
• Minimal TMR revenues expected until at least 2024

Takeaways

Artivion is executing against a multi-pronged growth strategy, but the path to sustained double-digit gains will depend on manufacturing execution, regulatory wins, and margin recovery.

• Stent Graft Supply Rebound: Operational fixes in Germany are essential to sustaining high teens-to-20% stent graft growth and meeting global demand.
• Margin and Profitability Path: Flat gross margins in 2023 set a baseline; meaningful EBITDA expansion hinges on cost discipline and product mix improvement.
• Pipeline and Market Expansion: Regulatory and clinical trial milestones in 2023-2025 could unlock significant new revenue streams and solidify Artivion’s competitive edge.

Conclusion

Artivion’s Q4 results showcase a business regaining operational footing and poised for growth, with clear catalysts ahead in both manufacturing and the regulatory pipeline. Sustained execution across supply chain, margin management, and new product launches will be decisive for realizing the company’s ambitious growth and profitability targets through 2024 and beyond.

Industry Read-Through

Artivion’s experience this quarter underscores broader medtech sector themes: labor market tightness is driving wage inflation and operational bottlenecks, but proactive hiring and supply chain optimization can restore growth trajectories. The company’s pivot away from low-priority legacy products (such as TMR) to focus on high-growth, high-margin therapies mirrors wider industry moves to streamline portfolios. Regulatory complexity, especially in the US and EU, continues to shape product launch timing and market access. Investors in the cardiac and vascular device space should watch for similar dynamics—particularly the importance of execution in emerging markets and the outsized impact of regulatory milestones on growth narratives.

AORT Healthcare Medical Devices Cardiac Surgery Stent Grafts Regulatory Margin Emerging Markets